Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and / or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and / or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Not Available
III
Rexer, Brent
NCT03529110
VICCBRE18126

Ketogenic Diet with Letrozole in Treating Patients with Estrogen Receptor Positive Breast Cancer

This early phase I trial studies how well ketogenic diet with letrozole works in treating patients with estrogen receptor positive breast cancer. Estrogen receptor positive breast cancer has special proteins on it, called estrogen receptors, that allow it to grow when exposed to estrogen. A ketogenic diet (low calorie, low carbohydrate) may help normalize abnormally high insulin levels that in turn may slow the growth of cancer cells. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.The purpose of this study is to learn if the combination of a 2 week ketogenic diet in combination with letrozole can help slow the growth of tumors.
Not Available
Early I
Rexer, Brent
NCT03962647
VICCBRE18108

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: